Under: Sexual Health
Best Peptides for Erectile Dysfunction
Improving blood flow, nerve function, and hormonal support for erectile function.
Erectile dysfunction involves insufficient blood flow, compromised nerve signaling, or hormonal imbalances that impair the physiological cascade necessary for penile tumescence. Research into peptide-based approaches focuses on mechanisms distinct from conventional pharmacology—for example, PT-141 (bremelanotide) targets melanocortin receptors in the central nervous system to modulate sexual arousal signals, while other peptides are being investigated for their effects on vascular function and nitric oxide production.
Research protocols for sexual dysfunction peptides typically involve subcutaneous injection or intranasal administration, with timing often coordinated to precede sexual activity by 30-120 minutes depending on the compound. Dosing frequency and duration vary significantly across studies and individual protocols, making consultation with qualified researchers essential for understanding appropriate administration patterns.
Peptides Studied for Erectile Dysfunction
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| PT-141 (Bremelanotide) PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. | high | — | |
| PT-141 (Bremelanotide) PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. | high | — |
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.